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Aims To compare characteristics of left ventricular assist device (LVAD) recipients receiving a cardiac implantable electronic
device (CIED) with a defibrillator component (implantable cardioverter-defibrillator and cardiac resynchronization
therapy with defibrillation, CIED-D) vs. those without one, and to assess whether carrying such a device contiguously
with an LVAD is associated with outcomes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Overall, 448 patients were analysed (mean age 52±13 years, 82% male) in the multicentre European PCHF-VAD
registry. To account for all active CIED-Ds during ongoing LVAD treatment, outcome analyses were performed by
a time-varying analysis with active CIED-D status post-LVAD as the time-varying covariate. At the time of LVAD
implantation, 235 patients (52%) had an active CIED-D. Median time on LVAD support was 1.1 years (interquartile
range 0.5–2.0 years). A reduction of 36% in the risk of all-cause mortality was observed in patients with an active
CIED-D [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.46–0.91; P = 0.012), increasing to 41% after
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adjustment for baseline covariates (HR 0.59, 95% CI 0.40–0.87; P = 0.008) and 39% after propensity score adjustment
(HR 0.61, 95% CI 0.39–0.94; P = 0.027). Other than CIED-D, age, LVAD implant as redo surgery, number of
ventricular arrhythmia episodes and use of vasopressors pre-LVAD were remaining significant risk factors of all-cause
mortality. Incident ventricular arrhythmias post-LVAD portended a 2.4-fold and 2.6-fold increased risk of all-cause
and cardiovascular death, respectively; carrying an active CIED-D remained associated with a 47% and 43% reduction
in these events, respectively.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions In an analysis accounting for all active CIED-Ds, including those implanted during LVAD support, carrying such a
device was associated with significantly better survival during LVAD support.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Advanced heart failure • Left ventricular assist devices • Cardiac implantable electronic device •
Implantable cardioverter-defibrillators • Cardiac resynchronization therapy •
Ventricular arrhythmia • Mortality
Introduction
It is estimated that patients with advanced heart failure (HF)
comprise 1–10% of the entire population of patients with HF,
with increasing prevalence paralleling the growth of the HF
population and the improvements in available treatments, pro-
longing survival.1 Advances in long-term mechanical circulatory
support with left ventricular assist devices (LVADs) have signifi-
cantly improved outcomes in this rapidly expanding population.2,3
However, several challenges in the clinical management of LVAD
recipients remain and several opportunities exist to further opti-
mize patient benefits,4–6 including combined device therapy with
cardiac implantable electronic devices (CIEDs).
Therapies for advanced HF are indicated with progression of
the disease beyond adequate symptom management or adequate
preservation of end-organ function, despite ongoing and optimised
guideline-directed medical and device therapies.1 For patients
with HF with reduced ejection fraction (HFrEF), the guidelines
mandate the use of implantable cardioverter-defibrillators (ICD)
and, in selected patients, cardiac resynchronization therapy (CRT)
devices.7 Given the progressive nature of the disease, a certain
amount of overlap of device-based treatment modalities is encoun-
tered – according to the INTERMACS database, 80% of LVAD
recipients already have an ICD device in situ.8 On the other hand,
patients may receive an LVAD without having a CIED when the
LVAD is indicated for an acute HF episode. Although the exist-
ing literature on patient outcomes with combined device therapy
is growing, the results are conflicting; the majority of the stud-
ies were conducted in single-centre patient populations, with few
exceptions.8–15 Importantly, a perspective on the European land-
scape of combined device therapy in advanced HF is still lacking.
The current International Society for Heart and Lung Transplan-
tation (ISHLT) guidelines for mechanical circulatory support pro-
vide a class I recommendation for the reactivation of an ICD after
LVAD surgery and a class IIa recommendation for ICD placement
after LVAD for those without one.16 However, more conservative
strategies have recently been advocated.17
We compared characteristics among patients receiving a CIED
with a defibrillator component (ICD and CRT-D devices) and
those without one in a multicentre European registry of LVAD ..
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. recipients to assess whether carrying a defibrillator component
contiguously with an LVAD, including CIEDs implanted post-LVAD,
was associated with improved outcomes.
Methods
Study population
This observational study enrolled patients through a network of 12
European HF tertiary referral centres, stemming from participants
and alumni of the Postgraduate Course in Heart Failure (PCHF) of
the Heart Failure Association of the European Society of Cardiology
and the European Heart Academy, forming the PCHF-VAD registry.
Each participating centre acquired the approval of their local institu-
tional/ethics review board for the study protocol and retrospective
acquisition of patient data, predominantly with a waiver of informed
consent.
Currently, the registry consists of 488 patients who underwent
durable ventricular assist device (VAD) implantation for advanced HF
and are in regular follow-up by the participating centres. The vari-
ables collected in the registry include baseline demographic patient
information, baseline device (VAD, ICD, CRT) information, patient
physical status and functional class, electrocardiographic and echocar-
diography data, laboratory findings, right heart catheterisation data,
data on medications and therapies as well as VAD and CIED param-
eters – except for baseline data, all other variables were collected at
three time points: prior to VAD implantation, at discharge from VAD
implantation, and 6 months after the last device implantation. In order
to represent the currently most utilised form of durable mechanical
circulatory support and to retain homogeneity of the studied cohort,
data were analysed for patients implanted with a continuous-flow LVAD
(cf-LVAD) – patients with pulsatile LVADs, right VADs and biventricu-
lar assist devices, as well as those with missing ICD/CRT carrier sta-
tus (including missing implantation/potential inactivation dates) were
excluded from the analysis. All cf-LVADs were implanted between 1
December 2006 and 15 April 2018. All-cause death was defined as
the primary outcome. The secondary outcomes were cardiovascular
mortality, hospitalisation for HF, the occurrence of clinically signifi-
cant ventricular arrhythmias (VAs) after LVAD implantation (defined
as symptomatic arrhythmias and/or arrhythmias leading to CIED
therapy delivery, and/or arrhythmias requiring medical intervention),
device-related (both LVAD and CIED) infections requiring antibiotic
treatment, intracranial bleeding and non-cerebral bleeding events. The
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adjudication of outcomes was performed by the teams of the registry
centres.
The patient data were collected and managed using REDCap
(Research Electronic Data Capture) electronic data capture tools – a
secure, web-based application,18 hosted at the University of Zagreb,
School of Medicine, which served as the data coordinating centre.
Statistical analysis
Baseline characteristics are expressed as counts and percentages for
categorical variables or as mean± standard deviation [alternatively,
median (25th–75th percentile) for those non-normally distributed]
for continuous variables. At baseline, the inter-group differences were
based on CIED with an active defibrillator component (CIED-D)
carrier status before LVAD implantation and were assessed using the
chi-square test or ANOVA (or Kruskal–Wallis test for non-normally
distributed variables) for categorical and continuous variables,
respectively.
Outcome analyses were performed using the primary endpoint of
all-cause death as well as the secondary outcomes. For survival analy-
ses, the time of LVAD implantation was considered as the index date;
the time of follow-up was defined as time to last contact, heart trans-
plant, weaning from LVAD or death (whichever came first). In order
to include in the analysis all active ICD and CRT-D devices during
the time of ongoing LVAD treatment (including those implanted and
excluding those inactivated during LVAD support), outcome analyses
were performed by a time-varying analysis with active CIED-D car-
rier status following LVAD implantation as the time-varying covari-
ate to assess the association between active CIED-D carrier status
post-LVAD and the occurrence and time course of the primary out-
come. The incidence rate was estimated for the primary and secondary
endpoints based on the time-varying covariate (active CIED-D car-
rier post-LVAD), and the hazard ratios (HR) were estimated using
the Cox proportional hazards model with the group of patients
with no active CIED-D post-LVAD serving as the referent group. A
Cox regression model based on a forward stepwise selection pro-
cess with a significance level of 0.05 and 0.10 for entry and removal
thresholds, respectively, was used to test the association of active
CIED-D carrier status with 25 baseline covariates (online supplemen-
tary Methods S1) that significantly differed between the two patient
groups at baseline and had less than 30% missing data: age, gen-
der, CIED-D status, heart rate, LVAD type, LVAD intention, INTER-
MACS class, aetiology of HF, known history of: chronic kidney disease,
atrial fibrillation/flutter, VAs; significant VAs pre-LVAD, prior cardiac
surgery, concomitant procedure with LVAD implant, type of life sup-
port prior to LVAD, diuretic use, beta-blocker use, ivabradine use,
mineralocorticoid receptor antagonist use, vasopressor use, ultrafiltra-
tion, type of mechanical ventilation, creatinine values, left ventricular
internal dimension at end-diastole, and LVAD implant date quartile
(Table 1).
Additional sensitivity analyses were performed to determine the
consistency of the results. A multiple imputation was performed
whereby missing data were managed using multiple imputation by
chained equations (STATA mi impute chained). Imputation was per-
formed for each variable with 1–30% of missing data; it was based on
linear regression using 20 baseline clinical variables and 18 predictor
variables and estimated over 30 imputations.19 Furthermore, in order
to additionally adjust for the differences between the patients grouped
by CIED-D carrier status prior to LVAD implantation (Table 1), we cre-
ated a propensity score to determine the possibility of having a CIED-D ..
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.. pre-LVAD. The propensity score was calculated using a multivariable
logistic regression model including the following variables: ICD/CRT
carrier status, age, gender, previous history of hypertension, diabetes,
chronic kidney disease, coronary artery disease, myocardial infarc-
tion, cerebrovascular accident, atrial fibrillation and VAs; type of LVAD,
intention of LVAD treatment, INTERMACS score, LVAD implant as
redo surgery and concomitant surgical procedures. This was followed
by a propensity score adjusted analysis to assess the relation of CIED-D
carrier status and the occurrence of the primary and secondary out-
comes. Finally, to control for immediate perioperative deaths, we have
utilised the time-varying coefficient to test the interaction between
the duration of follow-up and the CIED-D treatment effect at 30 and
90 days following LVAD implantation.
A P-value of < 0.05 was considered statistically significant. The
statistical analyses were performed in Stata version 14 (StataCorp,
College Station, TX, USA).
Results
Baseline characteristics
After excluding data from 14 patients with pulsatile LVADs and
biventricular assist devices, as well as 26 patients with missing
ICD/CRT carrier status (including missing implantation and poten-
tial inactivation dates), the analysed population consisted of 448
patients (Figure 1). The baseline clinical characteristics were col-
lected prior to LVAD implantation; the patients were thus divided
into two groups according to CIED-D status before LVAD implan-
tation: 240 patients (54%) were an CIED-D carrier pre-LVAD,
while the remaining 208 patients (46%) did not carry any of these
devices pre-LVAD (of note, the discrepancies such as the 20 ICD
patients in the non-CIED-D group are those that cross-over dur-
ing the course of LVAD treatment) (Figure 1). Baseline charac-
teristics of the patient population according to CIED-D status
pre-LVAD are provided in Table 1 and in the online supplementary
Table S1. CIED-D carriers were older and more frequently male
compared to those without CIED-D pre-LVAD. Of the patients
receiving a CIED-D pre-LVAD, the majority were those implanted
with an LVAD in the last quartile of LVAD implantation dates,
i.e. from 21 July 2016 onwards (online supplementary Figure S1).
The predominant disease aetiology was dilated cardiomyopathy in
those with CIED-D, while ischaemic cardiomyopathy was more
common in the other group. While chronic kidney disease was
more represented in CIED-D carriers, other co-morbidities such
as hypertension, diabetes mellitus, coronary artery disease, chronic
obstructive pulmonary disease and prior cerebrovascular acci-
dent did not differ significantly between the two groups. Known
atrial fibrillation and previous VAs (defined as those requiring
ICD therapy or external defibrillation prior to LVAD implanta-
tion verified in ICD memory or during patient monitoring) were
more frequent in the CIED-D pre-LVAD group. Although left
ventricular ejection fraction did not differ significantly between
groups, patients with CIED-D pre-LVAD had larger left ventricles.
Haemodynamic measurements did not reveal a significant differ-
ence between groups, nor did their blood pressure values. How-
ever, heart rate was significantly higher in those without CIED-D
pre-LVAD.
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Table 1 Baseline characteristics of the studied patients by CIED-D carrier status prior to left ventricular assist device
implantation
Overall
average
No CIED-D
pre-LVAD
(n = 208)
CIED-D
pre-LVAD
(n = 240)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 52±13 50± 14 54± 12 <0.001
Female sex 81 (18.1) 46 (22.1) 35 (14.6) 0.039
Geographical area 0.14
Northwest Europe (The Netherlands, Belgium,
Germany)
303 (76.6) 148 (71.2)
(48.8% of region)
155 (64.6)
(51.2% of region)
Southeast Europe
(Croatia, Poland, Lithuania, Italy, Spain, Greece)
145 (32.4) 60 (28.8)
(41.4% of region)
85 (35.4)
(58.6% of region)
Quartiles of date of LVAD implant <0.001
1st quartile
(6 Dec 2006–2 Jan 2012)
112 (25) 72 (34.6) 40 (16.7)
2nd quartile
(3 Jan 2012–8 Dec 2014)
112 (25) 62 (29.8) 50 (20.8)
3rd quartile
(9 Dec 2014–20 Jul 2016)
113 (25.2) 48 (23.1) 65 (27.1)
4th quartile
(21 Jul 2016–04 Apr 2018)
111 (24.8) 26 (12.5) 85 (35.4)
ICD status <0.001
No ICD 238 (53.1) 188 (90.4) 50 (20.8)
Primary prevention 153 (34.2) 15 (7.2) 138 (57.5)
Secondary prevention 57 (12.7) 5 (2.4) 52 (21.7)
CRT status <0.001
No CRT 345 (77.0) 188 (90.4) 157 (65.4)
CRT-P carrier 16 (3.6) 16 (7.7) 0 (0.0)
CRT-D carrier 87 (19.4) 4 (1.9) 83 (34.6)
Heart rate, b.p.m. 85± 20 93± 21 80± 17 <0.001
SBP, mmHg 100± 15 101± 16 100±14 0.71
DBP, mmHg 65±11 65± 12 65± 10 0.91
BMI, kg/m2 25.8± 4.6 25.3± 4.4 26.2± 4.8 0.050
NYHA class 0.06
II 15 (3.8) 5 (2.9) 10 (4.5)
IIIa 132 (33.4) 58 (33.3) 74 (33.5)
IIIb 105 (26.6) 37 (21.3) 68 (30.8)
IV 143 (36.2) 74 (42.5) 69 (31.2)
LVAD type <0.001
Heart Mate II 246 (54.9) 144 (69.2) 102 (42.5)
HeartWare HVAD 94 (21.0) 36 (17.3) 58 (24.2)
Heart Mate 3 87 (19.4) 22 (10.6) 65 (27.1)
Other 21 (4.7) 6 (2.9) 15 (6.2)
LVAD intention <0.001
BTT 305 (71.1) 137 (68.8) 168 (73.0)
BTD 68 (15.9) 47 (23.6) 21 (9.1)
DT 56 (13.1) 15 (7.5) 41 (17.8)
INTERMACS class <0.001
1 73 (16.7) 55 (27.4) 18 (7.6)
2 121 (27.7) 63 (31.3) 58 (24.6)
3 139 (31.8) 47 (23.4) 92 (39.0)
4–7 104 (23.8) 36 (17.9) 68 (28.8)
Aetiology of heart failure <0.001
Dilated cardiomyopathy 190 (42.4) 68 (32.7) 122 (50.8)
Ischaemic cardiomyopathy 206 (46.0) 104 (50.0) 102 (42.5)
Other 52 (11.6) 36 (17.3) 16 (6.7)
© 2019 The Authors
European Journal of Heart Failure © 2019 European Society of Cardiology
CIED with a defibrillator component in LVAD carriers 1133
Table 1 Continued
Overall
average
No CIED-D
pre-LVAD
(n = 208)
CIED-D
pre-LVAD
(n = 240)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Co-morbidities
Arterial hypertension 102 (22.8) 47 (22.6) 55 (22.9) 0.94
Diabetes mellitus 90 (20.1) 37 (17.8) 53 (22.1) 0.26
Chronic kidney disease 102 (22.8) 31 (14.9) 71 (29.6) <0.001
Coronary artery disease 111 (24.8) 52 (25.0) 59 (24.6) 0.92
Prior MI 168 (37.5) 87 (41.8) 81 (33.8) 0.08
Prior coronary revascularization 132 (29.5) 66 (31.7) 66 (27.5) 0.33
COPD 42 (9.4) 14 (6.7) 28 (11.7) 0.07
Atrial fibrillation/flutter 128 (28.6) 31 (14.9) 97 (40.4) <0.001
Ventricular arrhythmias 102 (22.8) 30 (14.4) 72 (30.0) <0.001
Cerebrovascular events 33 (7.4) 12 (5.8) 21 (8.8) 0.23
Significant ventricular arrhythmias prior to VAD implant <0.001
None 245 (66.9) 120 (83.3) 125 (56.3)
1 episode 58 (15.8) 14 (9.7) 44 (19.8)
2 episodes 25 (6.8) 5 (3.5) 20 (9.0)
3 episodes 21 (5.7) 2 (1.4) 19 (8.6)
≥ 4 episodes 17 (4.6) 3 (2.1) 14 (6.3)
Prior cardiac surgery 55 (12.3) 33 (15.9) 22 (9.2) 0.031
Concomitant procedure with LVAD implant 79 (17.6) 50 (24.0) 29 (12.1) <0.001
Life support prior to LVAD implant <0.001
None 318 (73.6) 112 (56.0) 206 (88.8)
ECMO 35 (8.1) 30 (15.0) 5 (2.2)
Temporary LVAD 4 (0.9) 4 (2.0) 0 (0.0)
Temporary BiVAD 1 (0.2) 1 (0.5) 0 (0.0)
IABP 55 (12.7) 35 (17.5) 20 (8.6)
Other 19 (4.4) 18 (9.0) 1 (0.4)
Medications
Diuretic 349 (90.6) 130 (79.3) 219 (99.1) <0.001
Beta blocker 230 (64.1) 64 (43.5) 166 (78.3) <0.001
ACEi/ARB 183 (49.5) 78 (49.7) 105 (49.3) 0.94
MRA 243 (72.8) 76 (55.9) 167 (84.3) <0.001
Ivabradine 36 (11.6) 9 (7.1) 27 (14.7) 0.042
Inotrope 232 (65.5) 104 (68.9) 128 (63.1) 0.25
Vasopressor 36 (10.8) 23 (16.8) 13 (6.6) 0.003
Ultrafiltration 12 (3.6) 10 (7.4) 2 (1.0) 0.003
Mechanical ventilation <0.001
None 310 (92.3) 116 (84.1) 194 (98.0)
NIV/cPAP 2 (0.6) 2 (1.4) 0 (0.0)
Intubation 24 (7.1) 20 (14.5) 4 (2.0)
Laboratory values
Creatinine, μmol/L 126± 57 117± 57 133± 56 0.004
Bilirubin, μmol/L 19.0 (12.0–30.8) 19.8 (12.0–34.0) 18.8 (12.0–28.0) 0.19
Echocardiographic data
LVIDd, mm 70.4± 12.8 67.4± 13.1 72.5±12.2 <0.001
LVEF, % 19± 7 19± 8 20± 7 0.46
Values expressed as mean± standard deviation, number (%), or median (interquartile range).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BiVAD, biventricular assist device; BMI, body mass index; BTD, bridge to decision; BTT,
bridge to transplantation; CIED-D, cardiac implantable electronic device with a defibrillator component; COPD, chronic obstructive pulmonary disease; cPAP, continuous
positive airway pressure; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy with a defibrillator component; CRT-P, cardiac resynchronization
therapy with a pacemaker component; DBP, diastolic blood pressure; DT, destination therapy; ECMO, extracorporeal membrane oxygenation; FAC, fractional area change;
IABP, intra-aortic balloon pump; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; LVIDd, left ventricular intraventricular dimension in
end-diastole; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NIV, non-invasive ventilation; NYHA, New York Heart Association; RVIDd, right ventricular
intraventricular dimension in end-diastole; SBP, systolic blood pressure; VAD, ventricular assist device.
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488 patients in registry
14 patients with non-
cfLVAD and BiVAD
26 patients with missing
CIED status (including
implant dates)
Data from 448 patients
analysed
CIED-D implanted/
activated in 20 patients
after LVAD implant
CIED-D explanted/
inactivated in 45 patients
after LVAD implant
235 patients with
active CIED-D
at LVAD implant
213 patients without
active CIED-D
at LVAD implant
5 patients with CIED-D
explant/inactivation
at LVAD implant
240 patients with
CIED-D pre-LVAD
208 patients without
CIED-D pre-LVAD
448 patients
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Figure 1 (Left) Selection of the study population from the PCHF-VAD registry. (Right) Patient flow during the follow-up period in respect
to a cardiac implantable electronic device (CIED) with a defibrillator component (CIED-D). BiVAD, biventricular assist device; cfLVAD,
continuous-flow left ventricular assist device; LVAD, left ventricular assist device.
The distribution of LVAD types differed significantly: those with
CIED-D were more frequently carriers of HeartWare HVAD and
HeartMate 3 devices than patients in the other subgroup, where
HeartMate II was more common. The proportion with an LVAD as
a bridge to decision was higher in those without a CIED-D; these
patients were also more frequently in INTERMACS classes 1 and
2, while no significant difference in New York Heart Association
(NYHA) class was noted. The proportion of patients on diuretics,
beta-blockers and mineralocorticoid receptor antagonists was
higher in those with a CIED-D pre-LVAD. A higher proportion
of patients without a CIED-D pre-LVAD was treated with vaso-
pressor medications (but not inotropes) and was on life support,
predominantly intra-aortic balloon pump and extracorporeal
membrane oxygenation. LVAD implantation as redo surgery as
well as concomitant surgical procedures were more frequent in
this group as well. In the group with CIED-D pre-LVAD, 58% of
the patients carrying an ICD received it for primary prevention;
44% of the patients without a CIED-D pre-LVAD and 34% of those
with such a device were transplanted (39% of the entire cohort).
Twenty patients received a CIED-D post-LVAD (9.6% of those
without a CIED-D pre-VAD), at a median time to CIED-D
implant of 57 days [interquartile range (IQR) 29.5–243.5 days,
range 0–1068 days]. Forty-five patients (19% of those with a
CIED-D pre-VAD) had their ICD or CRT-D device deacti-
vated post-LVAD at a median time of deactivation of 252 days
(IQR 77–379 days, range 0–981 days). Of these deactivations, 11
occurred during active LVAD support (median time to deactivation
40 days; IQR 0–368 days, range 0–664 days), while in the remaining
34 patients the deactivation occurred due to heart transplantation,
i.e. on the day of transplantation (Figure 1 and online supplementary
Figure S2). ..
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.. All-cause mortality and active CIED-D
carrier status following left ventricular
assist device implantation
The median time on LVAD support was 1.1 years (IQR
0.5–2.0 years) starting at the time of LVAD implantation (online
supplementary Figure S3), which was similar in those with active
CIED-D carrier status during LVAD support and those without
one (median 1.1 years, IQR 0.5–2.0 years; and 1.1 years, IQR
0.4–2.0 years, respectively). At the time of LVAD implantation,
213 patients (48%) did not have a CIED-D and 235 patients (52%)
had such a CIED in situ and activated (Figure 1). The primary
outcome of all-cause death occurred in a total of 134 patients
(30% of the overall study population). A total of 68 patients
remained in the non-CIED-D group and 55 remained in the
CIED-D group and suffered from all-cause death. Five patients
had the CIED-D deactivated and six entered the CIED-D group
before the event. The incidence rates for all-cause death were 28
events per 100 patient-years [95% confidence interval (CI) 22–36
events] and 18 events per 100 patient-years (95% CI 14–23
events) for those without and with a CIED-D after LVAD implant,
respectively (Table 2). One-year survival in the overall cohort was
80.1%. The rate of all-cause death was the greatest in the first
30 days post-LVAD implant (event rate 7.3% per month; 95% CI
5.2–10.4%), declined between 30 and 90 days (event rate 3.0%
per month; 95% CI 2.0–4.5%) and between 90 days and 1 year
(event rate 1.3% per month; 95% CI 0.9–1.8%), remaining stable
after 1 year (event rate 1.4% per month; 95% CI 1.0–1.9%).
In a time-varying analysis, the unadjusted HR demonstrated a
36% reduction in the risk of all-cause mortality in patients with
an active CIED-D following LVAD implantation (HR 0.64; 95%
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Table 2 Incidence rates and hazard ratios for the primary endpoint (all-cause death), cardiovascular mortality, heart
failure hospitalisation, ventricular arrhythmias post-left ventricular assist device (LVAD), device-related infection
requiring systemic antibiotics, non-cerebral and intracranial bleeding by time-updated CIED-D carrier status
following LVAD implantation
No CIED-D at LVAD
implant (n = 213)
CIED-D at LVAD
implant (n = 235)
HR (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unadjusted Adjusteda
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
All-cause mortality
(n of events = 134)
28.2
(22.4–35.5)
18.1
(14.1–23.2)
0.64 (0.46–0.91)
P = 0.012
0.59 (0.40–0.87)
P = 0.008
Cardiovascular mortality
(n of events = 83)
16.7
(12.4–22.5)
11.9
(8.7–16.2)
0.72 (0.46–1.11)
P = 0.13
0.65 (0.39–1.07)
P = 0.09
Heart failure hospitalisation
(n of events = 80)
11.9
(8.3–17.1)
17.8
(13.5–23.4)
1.50 (0.96–2.38)
P = 0.08
0.92 (0.56–1.51)
P = 0.74
Ventricular arrhythmias
post-LVAD
(n of events = 107)
14.0
(9.9–19.8)
31.3
(24.9–39.2)
2.20 (1.46–3.34)
P< 0.0001
1.57 (0.98–2.52)
P = 0.06
Device-related infection requiring
systemic antibiotics
(n of events = 149)
39.1
(31.1–49.2)
28.1
(22.4–35.2)
0.76 (0.55–1.05)
P = 0.09
0.96 (0.66–1.40)
P = 0.84
Non-cerebral bleeding
(n of events = 88)
19.5
(14.5–26.3)
15.5
(11.5–20.8)
0.79 (0.52–1.20)
P = 0.27
0.64 (0.40–1.03)
P = 0.07
Intracranial bleeding
(n of events = 32)
6.3
(3.9–10.3)
4.8
(3.0–7.9)
0.75 (0.37–1.52)
P = 0.42
0.55 (0.24–1.26)
P = 0.16
The incidence rates are presented as number of events per 100 patient-years (95% CI).
CI, confidence interval; CIED-D, cardiac implantable electronic device with a defibrillator component; HR, hazard ratio.
aAdjusted for age, number of ventricular arrhythmia episodes before LVAD implantation, use of vasopressors prior to LVAD implantation, LVAD type and LVAD implant as a
redo surgical procedure.
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Figure 2 Kaplan–Meier plot of time to all-cause mortality,
according to CIED-D carrier status following left ventricular assist
device (LVAD) implantation. The analysis time begins at the time
of LVAD implantation. CIED-D status 0 stands for no CIED-D
present post-LVAD, CIED-D status 1 stands for CIED-D present
post-LVAD. CIED-D, cardiac implantable electronic device with a
defibrillator component; HR, hazard ratio.
CI 0.46–0.91, P = 0.012) (Figure 2 and Table 2). No significant
alteration in the treatment effect after 30 or 90 days following
LVAD implantation was found (interaction P = 0.68 and P = 0.07,
respectively).
Using stepwise regression, CIED-D carrier status, age, number
of VA episodes before LVAD implantation, use of vasopressors ..
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.. prior to LVAD implantation, LVAD type and LVAD implant as a
redo surgical procedure were identified as independently significant
of all-cause mortality. After adjustment for these variables, the
HR for CIED-D post-LVAD status remained significant (0.59, 95%
CI 0.40–0.87; P = 0.008). Age, LVAD implant as redo surgery,
number of VA episodes pre-LVAD and vasopressor use were the
remaining significant predictors of the primary outcome (Table 3).
Active CIED-D carrier status after LVAD implant remained sig-
nificant after adding active CRT with a pacemaker component
(CRT-P) carrier status post-LVAD implant to the model (HR 0.57,
95% CI 0.38–0.84; P = 0.005) (Table 3). Furthermore, the benefit
of CIED-D treatment on all-cause mortality remained significant
even after excluding patients with a CIED-D placed or deacti-
vated/removed following LVAD implantation, both in unadjusted
(HR 0.71, 95% CI 0.50–1.00; P = 0.048) and adjusted analysis (HR
0.63, 95% CI 0.41–0.96; P = 0.030). In a subgroup analysis, the
effect of treatment with a CIED-D following LVAD implantation
was consistent across various categorical subgroups at baseline
(Figure 3). Of note, exposure to ultrafiltration at baseline was asso-
ciated with a significant interaction P-value (0.0044), suggesting a
possible interaction effect: CIED-D therapy post-LVAD was asso-
ciated with a larger benefit in those not undergoing ultrafiltration
pre-LVAD implant (HR 0.63, 95% CI 0.42–0.94) compared to those
undergoing ultrafiltration (HR 7.76, 95% CI 1.07–56.0), however
only five patients in the latter subgroup died during follow-up
(hence not shown in the forest plot).
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Table 3 Multivariate Cox regression models of risk
factors for all-cause death by time-updated CIED-D
carrier status following left ventricular assist device
implantation
Variable HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CIED-D post-LVAD 0.59 (0.40–0.87) 0.008
Age 1.03 (1.02–1.05) <0.0001
LVAD implant as redo surgery 1.69 (1.09–2.61) 0.019
LVAD type 0.35
Heart Mate II Referent
Heart Ware 1.28 (0.81–2.02)
Heart Mate 3 0.73 (0.39–1.36)
Other 0.76 (0.33–1.72)
No. of VA episodes pre-LVAD 0.011
≥ 4 Referent
None 0.51 (0.23–1.14)
1 0.29 (0.11–0.79)
2 0.75 (0.28–1.97)
3 0.44 (0.14–1.38)
Unknown 0.21 (0.08–0.58)
Vasopressor use pre-LVAD 0.008
Yes Referent
No 0.49 (0.28–0.86)
Unknown 0.89 (0.47–1.70)
CIED-D post-LVAD 0.57 (0.38–0.84) 0.005
CRT-P post-LVAD 0.62 (0.25–1.59) 0.322
Age 1.03 (1.01–1.05) <0.0001
LVAD implant as redo surgery 1.74 (1.12–2.71) 0.014
LVAD type 0.349
Heart Mate II Referent
Heart Ware 1.27 (0.80–2.00)
Heart Mate 3 0.73 (0.39–1.36)
Other 0.73 (0.32–1.66)
No. of VA episodes pre-VAD 0.011
≥ 4 Referent
None 0.51 (0.23–1.16)
1 0.29 (0.11–0.79)
2 0.75 (0.28–1.97)
3 0.48 (0.15–1.50)
Unknown 0.21 (0.08–0.58)
Vasopressor use pre-LVAD 0.007
Yes Referent
No 0.48 (0.27–0.84)
Unknown 0.85 (0.45–1.64)
CI, confidence interval; CIED-D, cardiac implantable electronic device with
a defibrillator component; CRT-P, cardiac resynchronization therapy with a
pacemaker component; HR, hazard ratio; LVAD, left ventricular assist device;
VA, ventricular arrhythmia; VAD, ventricular assist device.
Secondary outcomes and active
ICD/CRT-D carrier status following left
ventricular assist device implantation
The occurrence of one or more episodes of symptomatic VAs
or those requiring intervention was noted in 24% of the entire ..
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.. cohort (107 patients): 30 patients remained in the non-CIED-D
group and 73 remained in the CIED-D group and suffered from
new-onset VAs, while two patients transitioned from the CIED-D
group and two entered the CIED-D group before their event
(the incidence rates are provided in Table 2). In patients with
a CIED-D, a VA episode requiring anti-tachycardia pacing (ATP)
occurred in 25 patients (median time to first ATP 231 days; IQR
25–495 days), while 42 patients received a shock (median time
to first shock 121 days; IQR 7–231 days); 29% of the CIED-D
cohort received at least one of these therapies. None of these
patients died on the day of therapy delivery. Patients with a
CIED-D post-LVAD had a nominally significant crude increased
risk of post-LVAD VAs which was no longer significant after
adjusting for the relevant baseline characteristics (HR 1.57, 95% CI
0.98–2.52, P = 0.06, adjusted by variable selection for the primary
outcome; Table 2 and online supplementary Tables S2 and S3).
We further used stepwise regression to detect variables that are
independently significant of the occurrence of VAs post-LVAD.
After additional adjustment for these variables, active CIED-D
post-LVAD status remained unrelated to the occurrence of this
secondary endpoint (online supplementary Table S2). An additional
analysis of incident VAs post-LVAD as a time-varying covariate
demonstrated that the occurrence of such arrhythmias portended
a 2.4-fold increased risk of all-cause death and a 2.6-fold increased
risk of cardiovascular death, while carrying an active CIED-D
remained associated with a significant 47% reduction in all-cause
death and 43% reduction in cardiovascular death. LVAD implant
as redo surgery, vasopressor use prior to LVAD implant and
increasing patient age were significantly associated with both of
these outcomes, while the occurrence of VAs pre-LVAD was
identified as an additional risk factor for all-cause death (online
supplementary Table S4).
The incidence rates for cardiovascular mortality, HF hospitalisa-
tion, device-related infection requiring systemic antibiotics, as well
as extracranial and intracranial bleeding events are presented in
Table 2. Cardiovascular death occurred in 83 patients: 40 remained
in the non-CIED-D group and 36 remained in the CIED-D group
and suffered from cardiovascular death, while three patients transi-
tioned from the CIED-D group and four entered the CIED-D group
before death from cardiovascular cause. The crude risk for cardio-
vascular mortality was not modified by CIED-D status, while in
the adjusted analysis there was a trend towards a reduction in the
risk of cardiovascular death with active CIED-D status (HR 0.65,
95% CI 0.39–1.07; P = 0.09) (online supplementary Tables S3 and
S4). Both the crude and adjusted risks for the remaining outcomes
were not significantly modified by CIED-D post-LVAD (Table 2 and
online supplementary Table S3; the full results of the multivariable
regression models for the remaining outcomes are provided in the
online supplementary Tables S5 and S6).
Sensitivity analyses
In addition to a forward variable selection procedure, we have also
performed a backwards selection, according to which CIED-D car-
rier status, age, disease aetiology, number of VA episodes before
LVAD, LVAD type, intention of LVAD therapy, use of vasopressors,
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Treatment Effect  by Subgroup
Interaction Favors Intervention Favors Control
Overall
gender
Male
Female
Dilated
Ischemic
Other
Aetiology
p = 0.25
p = 0.85
p = 0.15
p = 0.37
p = 0.25
p = 0.65
p = 0.92
p = 0.08
p = 0.10
p = 0.63
p = 0.27
.5
Hazard Ratio
1 1.5 2 2.5 3.5 44.553
CKD
AF
VA
Number of VA episodes pre-LVAD
0
1
0
1
0
1
0
1
0
1
0
1
2
3
4≥
4≥
Heart Mate II
Heart Mate 3
Other
BTT
BTD
DT
1
2
3
Heart Ware
LVAD type
LVAD Intention
INTERMACS calss
Redo surgery
Vasopressor use pre-LVAD
Figure 3 The effect of treatment with a cardiac implantable electronic device with a defibrillator component following left ventricular assist
device (LVAD) implantation on all all-cause mortality for individual patient subgroups. 0 stands for absent, 1 for present. AF, atrial fibrillation;
BTD, bridge to decision; BTT, bridge to transplant; CKD, chronic kidney disease; DT, destination therapy; VA, ventricular arrhythmia.
use of beta-blockers, type of mechanical ventilation implantation
and intention of LVAD therapy were identified as independently sig-
nificant of all-cause mortality. After adjustment for these variables,
the results remained consistent with the primary analysis (HR 0.61,
95% CI 0.40–0.94; P = 0.024); the remaining significant predictors
of the primary outcome were age (HR per 1 year change in age:
1.04, 95% CI 1.02–1.06; P< 0.0001), vasopressor use pre-LVAD
(P = 0.0007), type of mechanical ventilation pre-LVAD (P = 0.025)
and number of episodes of VAs pre-LVAD (P = 0.028) (online sup-
plementary Table S7).
Given the significant differences in the baseline characteristics
between the two patient groups, we have additionally performed
a propensity score adjustment, following which the relative risk
of all-cause death remained significantly reduced in the CIED-D ..
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.. carriers (HR 0.60, 95% CI 0.39–0.94; P = 0.024), while the propen-
sity score itself was not significantly related to all-cause death.
Strong predictors of CIED-D carrier status included having a his-
tory of atrial fibrillation [odds ratio (OR) 2.9] or VAs (OR 2.0),
while having a prior myocardial infarction and a concomitant pro-
cedure with LVAD implant reduced the odds of carrying a CIED-D
(OR 0.5 and 0.4, respectively). LVAD type, LVAD intention and
INTERMACS class were additional predictors of CIED-D carrier
status (all P< 0.05) (online supplementary Table S8).
In order to account for missing data, additional sensitivity analy-
ses were performed by multiple imputation of missing values. The
results were consistent with the original analyses – when adjust-
ing by variable selection for the primary outcome, time-updated
active CIED-D carrier status, patient age and LVAD implantation as
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a redo surgical procedure remained the only significant predictors
of all-cause mortality (online supplementary Table S9). In an addi-
tional stepwise multiple regression model obtained from the multi-
ple imputation dataset, age and LVAD implantation as redo surgery
remained additional predictors of all-cause mortality, in addition to
active CIED-D status post-LVAD (online supplementary Table S10).
In an additional analysis of ICD-only carriers (excluding those
with a CRT-D device) contiguously with an LVAD, the crude
HR showed a trend towards a reduction in all-cause mortality
(HR 0.73, 95% CI 0.51–1.04; P = 0.077). However, in adjusted
analysis, carrying an ICD-only reached a significant reduction in
all-cause mortality (HR 0.60, 95% CI 0.39–0.92; P = 0.019, online
supplementary Table S11). After multiple imputation, the adjusted
HR remained consistent, suggesting a 35% reduction in all-cause
death in active ICD-only carriers during LVAD support (online
supplementary Table S11).
Discussion
In this analysis of the PCHF-VAD registry, we have described the
baseline characteristics and outcomes of 448 cf-LVAD carriers
from 12 European academic centres in relation to carrying a CIED
with an active defibrillator component (either in an ICD or CRT-D
device) during the course of LVAD support. In patients enrolled
in the registry, carrying an active defibrillator component during
LVAD support was associated with a reduced crude and adjusted
risk of all-cause mortality, compared to the patients without
an active defibrillator component. This finding was consistent in
several sensitivity analyses, including a propensity score adjusted
analysis. Higher patient age, LVAD implantation as a redo surgical
procedure, number of clinically significant VA episodes pre-LVAD
and use of vasopressors recognized as other significant predictors
of all-cause mortality.
The prevalence of either ICD or CRT-D carriers prior to LVAD
implantation of 54% in this cohort is notably lower than that of
> 80% of LVAD carriers with an ICD in recent analyses of the
INTERMACS and UNOS registries,8,9 while it is more comparable
to the EUROMACS population in which 58% carry an ICD.20
This points out an important difference between LVAD carriers
in Europe and the United States, while the currently available
data predominantly originate from US centres. The source of this
discrepancy is unclear but might be reflective of nearly four-fold
higher ICD implantation rates in the United States, compared
to Europe.21 The clinical profile of CIED-D carriers pre-LVAD
in our registry suggests a more chronic course of HF prior to
the initiation of LVAD support – these patients were in higher
INTERMACS classes with less need for life support therapies
(vasopressors, ultrafiltration or mechanical ventilation) prior to
LVAD; they had more remodelled left ventricles and a higher use
of guideline-mandated HF therapies, including beta-blockers that
may supress ventricular ectopy, compared to patients without
an CIED-D pre-LVAD. A more chronic profile corresponds to
ICD carriers described in other LVAD cohorts.10,11,13–15 However,
compared to several other analyses, the use of LVADs as bridge
to transplantation was much more frequent in our cohort.9,10 ..
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.. Furthermore, patients implanted with an LVADmore recently were
more likely to have received an CIED-D, as well as those with a
higher number of VAs pre-LVAD.
While the survival benefit of ICDs is well established in symp-
tomatic HFrEF patients,7 the data on the utility of defibrillators in
LVAD carriers are still conflicting. Traditionally, LVAD patients are
considered to tolerate life-threatening VAs,22 possibly due to the
Fontan-like circulation that occurs when the fibrillating right ven-
tricle becomes a passive conduit.17 Conversely, in some patients
VAs may cause progressive right ventricular failure or lead to more
gradual HF and death. ‘Routine’ implantation of ICDs post-LVAD
is still debated and predominantly hindered by increased risk of
bleeding and infection in this high-risk population.23–25 Notwith-
standing this, the replacement of exhausted generators of defib-
rillators implanted prior to onset of LVAD therapy is increasingly
supported.16,17
While a meta-analysis of six observational studies assessing the
impact of ICDs on survival of LVAD patients reported a significant
reduction in mortality associated with ICD use, this finding was
not significant when confined to the cf-LVAD population.22 The
results of one of these studies suggested that only patients who
suffered potentially life-threatening VAs prior to LVAD implantation
had recurring arrhythmias after LVAD implantation, thus benefiting
from ICD therapy.10 However, the rate of all-cause death in
our multicentre cohort, and in particular the subgroup without
CIED-D post-LVAD, was notably higher in comparison to this
single-centre study, yet lower than reported from the EUROMACS
data, and similar to the INTERMACS report.8,10,26 In an analysis
of the UNOS registry, the presence of ICDs at listing in durable
LVAD recipients was not associated with lower waitlist mortality;
however, numerically fewer arrhythmic deaths were noted in the
ICD group.27 As mentioned, the penetration of ICDs in this
cohort is notably greater than in our European cohort which may
portend differences among the populations. In the largest currently
available analysis from the INTERMACS database, no survival
benefit was associated with ICD in VAD carriers: in the primary
analysis, ICD implantation was associated with increased mortality
of unexpected death, which had not met significance levels in
additional sensitivity analyses.8 While we can only speculate on
the aggregate causes of the discrepant results between our and
the INTERMACS registry, several features clearly differ between
these cohorts: the INTERMACS cohort was dominated by patients
in NYHA class IV (around 83% of patients in the propensity
score-matched cohort, as opposed to 36% of our cohort), a
much larger proportion of destination therapy patients (40%,
as opposed to only 13% of our population) and those with
prior cardiac surgery (68% in INTERMACS compared to 12%
in PCHF-VAD). Despite the fact that both studies identify clear
differences in outcomes between those with and without an ICD,
it is unclear whether the patient characteristics more typical for
the INTERMACS registry portended potentially harmful effects
of ICD therapy in that cohort. Importantly, in addition to a
much larger penetration of ICDs within the LVAD population
compared to our European registry, the INTERMACS analysis
excluded patients with de-novo ICDs after LVAD implantation.
As such, possible ‘crossover’, i.e. initiation and/or termination
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of CIED therapy during active LVAD support warrants to be
accounted for.
We have thus utilised a time-varying analysis that has pro-
vided consistent results: in an unadjusted analysis, carrying an
active CIED with a defibrillator component was associated with
a 36% reduction in all-cause death, which remained significant and
comparable after adjustment for the relevant baseline covariates
(41% reduction in all-cause death), after propensity score adjust-
ment (40% reduction), after adjustment for the occurrence of VAs
post-LVAD (47% reduction) and by utilising multiple imputation
to compensate for the missing data (37% reduction). Our anal-
ysis was expanded to carriers of both ICD and CRT-D devices
to include the effect of the defibrillator component in either type
of CIED. After additional adjustment for CRT-P carrier status, the
reduction in the risk of all cause-death remained significant and
reached 43%. Furthermore, in a sub-analysis of the ICD-only sub-
group, the crude HR suggested a trend towards reduced all-cause
death, while the adjusted analysis confirmed a 40% reduction in
all-cause death in active ICD-only carriers during LVAD support.
The benefit of active CIED-D therapy with an LVAD remained con-
sistent in subgroup analyses as well as with additional sensitivity
analyses.
Ventricular arrhythmias post-LVAD occurred in 24% of our
cohort, which is within the reported range of 22–52%.8 In
the MOMENTUM 3 trial, sustained ventricular tachyarrhythmias
occurred relatively frequently (18% in centrifugal-flow VADs, 20%
in axial-flow VADs), but rarely resulted in death.3 While our data
suggested a nominally increased crude risk of developing clinically
significant VAs post-LVAD in CIED-D carriers (Table 2), this did not
remain significant in adjusted analyses and was likely an effect of
enhanced arrhythmia monitoring provided by the CIED. While we
cannot infer causality between the delivery of defibrillator-driven
therapies and reduction in mortality, we have noted that nearly one
third of the CIED-D carriers received at least one of these ther-
apies on at least one occasion, with a median time to first ATP
or shock well beyond the arrhythmically fragile early post-surgical
period. Moreover, in an analysis of incident VAs post-LVAD as a
time-varying covariate, the occurrence of the arrhythmia was a
strong predictor of all-cause and cardiovascular mortality as was
increasing patient age, LVAD implant as redo surgery and vaso-
pressor use prior to LVAD, while the presence of an active CIED-D
device remained associated with a reduction in the risk of all-cause
death. Whether the optimal timing of CIED-D implantation is
before or after LVAD remains to be explored.
Limitations
Our analysis was limited by typical features of retrospective registry
studies: incompleteness of the dataset which we aimed to account
for by multiple imputation methods, possible selection bias and
misclassification of events. Furthermore, the study was limited by
lack of data on arrhythmic events in non-CIED-D carriers. We
acknowledge the limited possibility of determining causality with a
retrospective analysis, as well as the ability to adequately adjudicate
the endpoints which also limits the possibility of determining
the mitigation of risk of arrhythmic deaths by a CIED-D. Finally, ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. this type of study design does not allow optimal control for
multiple potential confounders, however extensive adjustments
have confirmed the robustness of our results in terms of reduced
all-cause mortality with CIED-D post-LVAD, whereby all adjusted
models for all-cause death show a stronger treatment effect of
CIED-D. However, only a randomised prospective trial, which we
believe is warranted, would be able to adequately address this
clinically relevant topic.
Conclusion
In an LVAD cohort with granularly described baseline data stem-
ming from a multicentre European registry, we report a signifi-
cant reduction in the crude and adjusted risk of all-cause death
in patients carrying a CIED with an active defibrillator compo-
nent during LVAD support, which was consistent across sensitivity
analyses. Higher patient age, number of clinically significant VAs
pre-LVAD, use of vasopressors and LVAD implantation as redo
surgery were recognized as other significant predictors of all-cause
mortality.
Finally, an analysis of incident VAs post-LVAD confirmed its
occurrence as a strong predictor of all-cause and cardiovascular
mortality, while in this analysis the presence of an active CIED-D
remained associated with a reduction in the risk of all-cause and
cardiovascular death.
Unambiguous disparities in CIED-D usage in LVAD recipients as
well as its impact on outcomes exist between European and US
cohorts. Further insight in the comparison of these populations
should improve the understanding of (non-)response to CIEDs,
while evidence from a randomised controlled trial would be antici-
pated to inform decisions on contiguous device usage in this grow-
ing patient population.
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